Cepeginterferon alfa-2B

DB12814InvestigationalProtein Based Therapies

Cepeginterferon alfa-2B is under investigation in clinical trial NCT01889433 (An Open-label Comparative Efficacy and Safety Study of Algeron (Cepeginterferon Alfa-2b) in Treatment-naive Patients With Chronic Hepatitis C).

Mechanism: Pharmacologically active on Interferon alpha/beta receptor (IFNAR)
Curator reviewed
Also known as: Algeron · Pegylated human interferon A-2B
Code names: Cepeginterferon alfa-2B

Resolves to

Compound

UNII6J022WTC4YCAS1192706-52-7

Clinical / RWD

ATCL03AB14

What you can answer from here — as of July 07, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

698Drug interactionsStructured to mechanism, not free text

3Clinical trialsPhase, status and sponsor resolved per trial

1ATC codeIncluding every combination product, plus 9 drug categories

4+ReferencesStructured and connected to the statements they support

Which companies are running trials of Cepeginterferon alfa-2B, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account